Term ends Nov 29, 2031 · Medium confidence
20-year base term ends Nov 29, 2031
Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 9,061,021), so the cap could be lower.
Nov 29, 2011
Nov 29, 2031
Oct 5, 2021
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 29, 2011, when application 13/306,781, the earliest non-provisional in its chain, was filed (this one was filed Mar 27, 2018) | Nov 29, 2031 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,853,377, US 9,061,021, US 9,956,271) | resolves to Nov 29, 2031, no earlier than this term, so no change | Medium confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 2 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 29, 2031 | Medium confidence |
This family
| US 8,853,377 | In force Nov 2031 | Nov 2031 |
| US 9,061,021 | In force no later than Nov 2031 | no later than Nov 2031 |
| US 9,956,271 | In force Nov 2031 | Nov 2031 |
| US 11,135,274 | this patent Nov 2031 | Nov 2031 |
| Application 17/465,287 | Pending not computed | not computed |
Assignments
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 6, 2019 Reel 49090, frame 160 | Guild, Braydon Charles; Heartlein, Michael; Derosa, Frank | Shire Human Genetic Therapies, Inc. | Assignment of Assignor's Interest |
| May 13, 2019 Reel 49154, frame 1 | Shire Human Genetic Therapies, Inc. | Rana Therapeutics, Inc. | Assignment of Assignor's Interest |
| May 20, 2019 Reel 49222, frame 201 | Rana Therapeutics, Inc. | Translate Bio, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
A terminal disclaimer resolved from the filed document, referencing US 8,853,377, US 9,061,021, US 9,956,271, ends no earlier than this term, so it caps nothing.